Analysts Set Expectations for Envoy Medical FY2026 Earnings

Envoy Medical, Inc. (NASDAQ:COCH) – Equities researchers at HC Wainwright boosted their FY2026 earnings per share estimates for Envoy Medical in a report released on Friday, August 21st. HC Wainwright analyst Y. Chen now anticipates that the company will earn ($0.31) per share for the year, up from their prior forecast of ($0.32). HC Wainwright has a “Buy” rating and a $2.00 price objective on the stock. The consensus estimate for Envoy Medical’s current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Envoy Medical’s Q2 2027 earnings at ($0.05) EPS, Q3 2027 earnings at ($0.04) EPS and FY2027 earnings at ($0.18) EPS.

A number of other analysts have also issued reports on COCH. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Envoy Medical in a report on Tuesday, July 21st. Loop Capital set a $2.00 price target on Envoy Medical in a report on Monday, July 27th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $2.00.

Envoy Medical Stock Performance

NASDAQ COCH opened at $0.75 on Tuesday. Envoy Medical has a twelve month low of $0.36 and a twelve month high of $1.89. The stock has a market capitalization of $57.60 million, a PE ratio of -0.98 and a beta of 1.90. The stock has a 50-day simple moving average of $0.70 and a 200 day simple moving average of $0.69.

Envoy Medical (NASDAQ:COCH) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01. The business had revenue of $0.05 million during the quarter, compared to analyst estimates of $0.05 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC raised its position in shares of Envoy Medical by 111.3% during the fourth quarter. Geode Capital Management LLC now owns 98,351 shares of the company’s stock valued at $65,000 after buying an additional 51,813 shares during the last quarter. CIBC Bancorp USA Inc. acquired a new stake in Envoy Medical during the third quarter worth about $60,000. Focus Partners Wealth acquired a new stake in Envoy Medical during the first quarter worth about $276,000. Finally, DSG Capital Advisors LLC bought a new position in Envoy Medical during the first quarter valued at about $416,000. Institutional investors own 8.59% of the company’s stock.

Envoy Medical Company Profile

Envoy Medical (NASDAQ:COCH) is a medical device company focused on non-invasive neuromodulation therapies for dysphagia, a swallowing disorder that affects patients following neurological events or due to degenerative conditions. The company’s lead technology delivers targeted electrical stimulation designed to strengthen the muscles and neural pathways involved in the swallowing process.

Envoy Medical’s flagship therapy has received regulatory clearance from the U.S. Food and Drug Administration and is being introduced through rehabilitation centers, speech-language pathology clinics and acute care hospitals.